FDA Approves TALVEY™ (talquetamab-tgvs) for the Treatment of Patients with Heavily Pretreated Multiple Myeloma August 16, 2023
FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate) for Treatment of Patients with BRCA+ve metastatic CRPC August 16, 2023
European Commission Approves LONSURF® (Trifluridine/tipiracil) in Combination With Bevacizumab in 3rd Line Refractory mCRC August 9, 2023
Jemperli (dostarlimab) + chemo approved in the US as 1L treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer August 9, 2023
European Commission Approves Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer August 2, 2023
VANFLYTA First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML July 27, 2023
European Commission approves fixed-duration Columvi (glofitamab) for people with R/R DLBCL July 19, 2023
Enhertu approved in China as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer July 19, 2023
European Commission Grants Conditional Marketing Authorization for Taiho’s LYTGOBI Tablets for the Treatment of Adults With Cholangiocarcinoma July 19, 2023
European Commission Grants Conditional Marketing Authorization for LYTGOBI Tablets for the Treatment of Adults With Cholangiocarcinoma July 11, 2023
FDA Grants Full Approval For Blincyto To Treat MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia June 28, 2023
TALZENNA + XTANDI Combo Receives FDA Approval for adult patients with HRR-mutated metastatic CRPC June 28, 2023
FDA Approves FoundationOne®LiquidCDx as a Companion Diagnostic for BRAFTOVI + Cetuximab combo to Identify Patients With BRAF V600E Alterations in mCRC June 14, 2023
Lynparza + abiraterone approved in the US for the treatment of BRCA-mutated metastatic CRPC June 6, 2023
VANFLYTA First FLT3 Inhibitor Approved in Japan for Patients with Newly Diagnosed FLT3-ITD Positive AML May 31, 2023
The China NMPA Approves TYVYT® + Bevacizumab + Chemotherapy in Patients with EGFR-mutated nsqNSCLC who Progressed after EGFR-TKI Therapy May 18, 2023
European Commission approves Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma May 18, 2023
European Commission granted approval to AKEEGA® (Niraparib & Abiraterone Dual Action Tablet) for the Treatment of Patients with metastatic CRPC with BRCA1/2 Mutations May 10, 2023
FDA approves Polivy in combination with R-CHP for people with certain types of 1L DLBCL April 27, 2023
